Sign In

Gilmore ONeill

Chief Medical Officer at Sarepta Therapeutics

Gilmore O'Neill is a prominent figure in the biopharmaceutical industry, currently serving as the Chief Executive Officer of Editas Medicine, a position he has held since June 2022. Prior to this role, he was the Executive Vice President of Research and Development and Chief Medical Officer at Sarepta Therapeutics from June 2018 until December 2021. His leadership at Sarepta was marked by overseeing the development of innovative therapies for rare neuromuscular diseases, particularly focusing on Duchenne muscular dystrophy (DMD) .135

Educational Background

Dr. O'Neill holds a Bachelor of Medicine degree from University College Dublin and a Master of Medical Sciences degree from Harvard Medical School, specializing in neurology. He also completed his residency in neurology at Massachusetts General Hospital .25

Career Highlights

  • Sarepta Therapeutics (2018-2021): At Sarepta, Dr. O'Neill was instrumental in leading clinical development and regulatory strategy for several RNA and gene therapeutic programs. His efforts contributed to the advancement of multiple pipeline candidates aimed at treating DMD and other conditions .135
  • Biogen (2003-2018): Before joining Sarepta, he spent over 15 years at Biogen, where he held various senior roles, including Senior Vice President of Late-Stage Clinical Development. He played a key role in the development and approval of significant drugs such as Spinraza® for spinal muscular atrophy and Tecfidera® for multiple sclerosis .234

Professional Affiliations

Dr. O'Neill is also involved with several organizations beyond his corporate roles:

  • He serves on the board of directors for UNITY Biotechnology, which focuses on therapeutics for age-related diseases.
  • He is a member of the American Academy of Neurology, reflecting his commitment to advancing neurological health .25

Vision and Impact

Throughout his career, Dr. O'Neill has been recognized for his deep expertise in neurobiology and genetic medicine, successfully guiding numerous clinical programs from inception through regulatory approval. His vision is centered on leveraging genetic medicine to improve patient outcomes, particularly for those with rare diseases .135

Highlights

Oct 30 · marketscreener.com
Gilmore O'Neill: Positions, Relations and Network - MarketScreener
Sep 11 · massbio.org
Gilmore O'Neill - MassBio
Gilmore O'Neill - MassBio
Aug 2 · biotechtv.com
How a new CEO has been trying to position Editas to execute on the ...
Aug 4 · Seeking Alpha
Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha
Aug 4 · Seeking Alpha
Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha
Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call Transcript - See
Jun 13 · pharmavoice.com
First 90 Days: Editas Medicine's Gilmore O'Neill - PharmaVoice
Apr 14 · biospace.com
Gilmore O'Neill “Excited” to Take the Reins at Editas Medicine
Gilmore O'Neill “Excited” to Take the Reins at Editas Medicine
Editas Medicine Appoints Gilmore O'Neill as Chief Executive Officer

Related Questions

What are Gilmore O'Neill's main responsibilities at Sarepta Therapeutics?
How did Gilmore O'Neill's role at Biogen prepare him for his position at Sarepta?
What are some of the key projects Gilmore O'Neill has worked on at Biogen?
How has Gilmore O'Neill's leadership style impacted Sarepta Therapeutics?
What are Gilmore O'Neill's educational background and qualifications?
Gilmore ONeill
Gilmore ONeill, photo 1
Gilmore ONeill, photo 2
Add to my network

Location

Greater Boston Area